Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹766.45
3.30 (0.43%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹18.60K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
31.8
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹432.6+77.2%
52W High₹804.3-4.7%
Current Price
₹766.45
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹613.16
Upper Circuit₹919.74
Reference Price
₹766.45
Investment Checklist
Double Bottom on 1W (BREAKOUT CONFIRMED) — target ₹724.15
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹619.7
Trend: Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
SuperTrend(10,3): Price above SuperTrend (Industry Standard (Swing/Medium-Term))
SuperTrend(7,3): Price above SuperTrend (Responsive Setting (Day Trading/Short-Term))
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
82%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
EMA20
761.39
EMA50
722.33
EMA200
618.74
Price Action
CONSOLIDATION
NEUTRAL
Higher Highs5
Higher Lows4
Lower Highs4
Lower Lows5
Support & Resistance Levels
Resistance (Above)
₹804.30
Support (Below)
₹761.40
₹721.15
₹640.00
₹625.85
₹616.05
Volume Analysis
TrendDECREASING
Change-63.40%
Unusual VolumeNo
Stop Loss Levels
Fixed Risk
1% Risk₹758.79
3% Risk₹743.46
5% Risk₹728.13
7% Risk (Custom)
₹712.80Technical Levels
1x ATR (Volatility)₹743.22
2x ATR (Swing)₹719.99
3x ATR (Trend)₹696.76
Immediate Support₹761.40
Moving Averages
EMA 20 (Medium-term)₹761.39
EMA 50 (Trend)₹722.33
EMA 200 (Long-term)₹618.74
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹1,196.8 Cr | ₹1,208.8 Cr | ₹1,294.7 Cr | ₹1,378 Cr |
| Net Profit | ₹152 Cr | ₹112.6 Cr | ₹130.6 Cr | ₹150.2 Cr |
| EPS | — | ₹4.64 | ₹5.38 | ₹6.19 |
| Operating Profit | ₹242.5 Cr | ₹237.1 Cr | ₹277.1 Cr | ₹304.5 Cr |
ROE
13.50%
ROCE
13.94%
Debt/Equity
0.39
Current Ratio
1.56
OPM
22.09%
NPM
10.90%
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 31 Jul 2025 | Dividend - Rs 1.50 Per Share | DIVIDEND |
| 30 Jul 2024 | Annual General Meeting/Dividend - Rs 1.50 Per Share | AGM |
| 03 Aug 2023 | Dividend - Rs 1.50 Per Share | DIVIDEND |
| 03 Aug 2023 | Annual General Meeting | AGM |
| 22 Aug 2022 | Buy Back | BUYBACK |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for GRANULES
View AllNEWS
neutral
Business Standard - Markets 10d ago
USFDA issues EIR for Chantilly facility of Granules Pharmaceuticals
GRANULESHealthcare
positive
CNBC TV18 - Markets 10d ago
Granules India shares gain after US unit gets EIR from USFDA
The USFDA classified the inspection as Voluntary Action Indicated (VAI), indicating that while certain observations were made, they do not warrant any regulatory or enforcement action.
GRANULESHealthcare
neutral
Google News - India Markets 16d ago
Granules India schedules analyst investor meeting on June 3 - scanx.trade
Granules India schedules analyst investor meeting on June 3scanx.trade
GRANULESHealthcare